Effect of tolcapone on brain activity during a variable attentional control task: A double-blind, placebo-controlled, counter-balanced trial in healthy volunteers

Sophia C. Magalona, Roberta Rasetti, Jingshan Chen, Qiang Chen, Ian Gold, Heather Decot, Joseph H. Callicott, Karen F. Berman, José A. Apud, Daniel Weinberger, Venkata Mattay

Research output: Contribution to journalReview article

Abstract

Background: Attention is the capacity to flexibly orient behaviors and thoughts towards a goal by selecting and integrating relevant contextual information. The dorsal cingulate (dCC) and prefrontal (PFC) cortices play critical roles in attention. Evidence indicates that catechol-O- methyltransferase (COMT) modulates dopaminergic tone in the PFC and dCC. Objective: In this study, we explored the effect of tolcapone, a CNS penetrant COMT inhibitor that increases cortical dopamine levels, on brain activity during a Variable Attentional Control (VAC) task. Study Design: We performed a double-blinded, placebo-controlled, counter-balanced trial with tolcapone (Tasmar, tablets, 100 mg three times a day for 1 day and then 200 mg three times a day for 6 days; ClinicalTrials.gov identifier: NCT00044083). Setting: The study was conducted in the Clinical Center of the National Institute of Mental Health from 2005 to 2009. Patients: Twenty healthy volunteers (11 males; mean age = 32.7 years) with good imaging and performance data on both arms of the study were investigated. Intervention: Participants underwent 3T blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) while performing the event-related VAC task, which varies attention over three levels of load: LOW, INT (intermediate), and HIGH. Main Outcome Measure: Changes in behavioral data and individual contrast images were analyzed using ANOVA with drug and task load as co-factors. Results: There was a significant main effect of increasing task load, with resulting decreased accuracy and increased reaction time. While there was no significant effect of tolcapone on these behavioral measures, the neuroimaging data showed a significant effect on load-related changes in dCC, with significantly lower dCC activation on tolcapone compared with placebo. Further, neural activity in dCC correlated positively with COMT enzyme activity (i.e., lower COMT activity and presumably more dopamine was associated with lower activation in dCC, i.e., more efficient information processing). Conclusion: Our results show that pharmacological reduction of COMT activity modulates the engagement of attentional mechanisms, selectively enhancing the efficiency of dCC processing in healthy volunteers, reflected as decreased activity for the same level of performance.

Original languageEnglish (US)
Pages (from-to)663-673
Number of pages11
JournalCNS Drugs
Volume27
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Catechol O-Methyltransferase
Healthy Volunteers
Placebos
Brain
Dopamine
National Institute of Mental Health (U.S.)
Prefrontal Cortex
Automatic Data Processing
Neuroimaging
Tablets
Reaction Time
Analysis of Variance
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
tolcapone
Pharmacology
Oxygen
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Effect of tolcapone on brain activity during a variable attentional control task : A double-blind, placebo-controlled, counter-balanced trial in healthy volunteers. / Magalona, Sophia C.; Rasetti, Roberta; Chen, Jingshan; Chen, Qiang; Gold, Ian; Decot, Heather; Callicott, Joseph H.; Berman, Karen F.; Apud, José A.; Weinberger, Daniel; Mattay, Venkata.

In: CNS Drugs, Vol. 27, No. 8, 08.2013, p. 663-673.

Research output: Contribution to journalReview article

Magalona, Sophia C. ; Rasetti, Roberta ; Chen, Jingshan ; Chen, Qiang ; Gold, Ian ; Decot, Heather ; Callicott, Joseph H. ; Berman, Karen F. ; Apud, José A. ; Weinberger, Daniel ; Mattay, Venkata. / Effect of tolcapone on brain activity during a variable attentional control task : A double-blind, placebo-controlled, counter-balanced trial in healthy volunteers. In: CNS Drugs. 2013 ; Vol. 27, No. 8. pp. 663-673.
@article{e5264d61ea7a469c87bd24b65c60d528,
title = "Effect of tolcapone on brain activity during a variable attentional control task: A double-blind, placebo-controlled, counter-balanced trial in healthy volunteers",
abstract = "Background: Attention is the capacity to flexibly orient behaviors and thoughts towards a goal by selecting and integrating relevant contextual information. The dorsal cingulate (dCC) and prefrontal (PFC) cortices play critical roles in attention. Evidence indicates that catechol-O- methyltransferase (COMT) modulates dopaminergic tone in the PFC and dCC. Objective: In this study, we explored the effect of tolcapone, a CNS penetrant COMT inhibitor that increases cortical dopamine levels, on brain activity during a Variable Attentional Control (VAC) task. Study Design: We performed a double-blinded, placebo-controlled, counter-balanced trial with tolcapone (Tasmar, tablets, 100 mg three times a day for 1 day and then 200 mg three times a day for 6 days; ClinicalTrials.gov identifier: NCT00044083). Setting: The study was conducted in the Clinical Center of the National Institute of Mental Health from 2005 to 2009. Patients: Twenty healthy volunteers (11 males; mean age = 32.7 years) with good imaging and performance data on both arms of the study were investigated. Intervention: Participants underwent 3T blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) while performing the event-related VAC task, which varies attention over three levels of load: LOW, INT (intermediate), and HIGH. Main Outcome Measure: Changes in behavioral data and individual contrast images were analyzed using ANOVA with drug and task load as co-factors. Results: There was a significant main effect of increasing task load, with resulting decreased accuracy and increased reaction time. While there was no significant effect of tolcapone on these behavioral measures, the neuroimaging data showed a significant effect on load-related changes in dCC, with significantly lower dCC activation on tolcapone compared with placebo. Further, neural activity in dCC correlated positively with COMT enzyme activity (i.e., lower COMT activity and presumably more dopamine was associated with lower activation in dCC, i.e., more efficient information processing). Conclusion: Our results show that pharmacological reduction of COMT activity modulates the engagement of attentional mechanisms, selectively enhancing the efficiency of dCC processing in healthy volunteers, reflected as decreased activity for the same level of performance.",
author = "Magalona, {Sophia C.} and Roberta Rasetti and Jingshan Chen and Qiang Chen and Ian Gold and Heather Decot and Callicott, {Joseph H.} and Berman, {Karen F.} and Apud, {Jos{\'e} A.} and Daniel Weinberger and Venkata Mattay",
year = "2013",
month = "8",
doi = "10.1007/s40263-013-0082-x",
language = "English (US)",
volume = "27",
pages = "663--673",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - Effect of tolcapone on brain activity during a variable attentional control task

T2 - A double-blind, placebo-controlled, counter-balanced trial in healthy volunteers

AU - Magalona, Sophia C.

AU - Rasetti, Roberta

AU - Chen, Jingshan

AU - Chen, Qiang

AU - Gold, Ian

AU - Decot, Heather

AU - Callicott, Joseph H.

AU - Berman, Karen F.

AU - Apud, José A.

AU - Weinberger, Daniel

AU - Mattay, Venkata

PY - 2013/8

Y1 - 2013/8

N2 - Background: Attention is the capacity to flexibly orient behaviors and thoughts towards a goal by selecting and integrating relevant contextual information. The dorsal cingulate (dCC) and prefrontal (PFC) cortices play critical roles in attention. Evidence indicates that catechol-O- methyltransferase (COMT) modulates dopaminergic tone in the PFC and dCC. Objective: In this study, we explored the effect of tolcapone, a CNS penetrant COMT inhibitor that increases cortical dopamine levels, on brain activity during a Variable Attentional Control (VAC) task. Study Design: We performed a double-blinded, placebo-controlled, counter-balanced trial with tolcapone (Tasmar, tablets, 100 mg three times a day for 1 day and then 200 mg three times a day for 6 days; ClinicalTrials.gov identifier: NCT00044083). Setting: The study was conducted in the Clinical Center of the National Institute of Mental Health from 2005 to 2009. Patients: Twenty healthy volunteers (11 males; mean age = 32.7 years) with good imaging and performance data on both arms of the study were investigated. Intervention: Participants underwent 3T blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) while performing the event-related VAC task, which varies attention over three levels of load: LOW, INT (intermediate), and HIGH. Main Outcome Measure: Changes in behavioral data and individual contrast images were analyzed using ANOVA with drug and task load as co-factors. Results: There was a significant main effect of increasing task load, with resulting decreased accuracy and increased reaction time. While there was no significant effect of tolcapone on these behavioral measures, the neuroimaging data showed a significant effect on load-related changes in dCC, with significantly lower dCC activation on tolcapone compared with placebo. Further, neural activity in dCC correlated positively with COMT enzyme activity (i.e., lower COMT activity and presumably more dopamine was associated with lower activation in dCC, i.e., more efficient information processing). Conclusion: Our results show that pharmacological reduction of COMT activity modulates the engagement of attentional mechanisms, selectively enhancing the efficiency of dCC processing in healthy volunteers, reflected as decreased activity for the same level of performance.

AB - Background: Attention is the capacity to flexibly orient behaviors and thoughts towards a goal by selecting and integrating relevant contextual information. The dorsal cingulate (dCC) and prefrontal (PFC) cortices play critical roles in attention. Evidence indicates that catechol-O- methyltransferase (COMT) modulates dopaminergic tone in the PFC and dCC. Objective: In this study, we explored the effect of tolcapone, a CNS penetrant COMT inhibitor that increases cortical dopamine levels, on brain activity during a Variable Attentional Control (VAC) task. Study Design: We performed a double-blinded, placebo-controlled, counter-balanced trial with tolcapone (Tasmar, tablets, 100 mg three times a day for 1 day and then 200 mg three times a day for 6 days; ClinicalTrials.gov identifier: NCT00044083). Setting: The study was conducted in the Clinical Center of the National Institute of Mental Health from 2005 to 2009. Patients: Twenty healthy volunteers (11 males; mean age = 32.7 years) with good imaging and performance data on both arms of the study were investigated. Intervention: Participants underwent 3T blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) while performing the event-related VAC task, which varies attention over three levels of load: LOW, INT (intermediate), and HIGH. Main Outcome Measure: Changes in behavioral data and individual contrast images were analyzed using ANOVA with drug and task load as co-factors. Results: There was a significant main effect of increasing task load, with resulting decreased accuracy and increased reaction time. While there was no significant effect of tolcapone on these behavioral measures, the neuroimaging data showed a significant effect on load-related changes in dCC, with significantly lower dCC activation on tolcapone compared with placebo. Further, neural activity in dCC correlated positively with COMT enzyme activity (i.e., lower COMT activity and presumably more dopamine was associated with lower activation in dCC, i.e., more efficient information processing). Conclusion: Our results show that pharmacological reduction of COMT activity modulates the engagement of attentional mechanisms, selectively enhancing the efficiency of dCC processing in healthy volunteers, reflected as decreased activity for the same level of performance.

UR - http://www.scopus.com/inward/record.url?scp=84880799337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880799337&partnerID=8YFLogxK

U2 - 10.1007/s40263-013-0082-x

DO - 10.1007/s40263-013-0082-x

M3 - Review article

C2 - 23794107

AN - SCOPUS:84880799337

VL - 27

SP - 663

EP - 673

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 8

ER -